One of the major genetic insights into the pathogenesis of polycythaemia vera included the identification of the somatic point gain-of-function mutations in Janus kinase 2 gene—first JAK2V617F on exon 14, present in 95%–97% of the cases, and later on exon 12. In the literature, we can find some reported studies where different exon 12 mutations are identified. Unlike patients with JAK2V617F mutation in exon 14, the mutation at exon 12 is not usually associated with an increase in the three haematopoietic series (erythrocytosis, leucocytosis and thrombocytosis). It appears to be associated with a distinct syndrome, mostly characterised by isolated and more marked erythrocytosis, independently of the mutational variant. We report here the case of a patient who is JAK2exon 12 positive, presenting a novel mutation—c.1605G>T (p.Met535Ile)—associated with c.1612C>T (p.His538Tyr) mutation previously described, evidencing an atypical clinical phenotype.
- myeloproliferative disease
- cancer genetics
- diagnostics haemato-oncology
- molecular genetics
Statistics from Altmetric.com
ASAP and APSA contributed equally.
Handling editor Mary Frances McMullin.
Contributors ASAP, APdSA: both authors contributed equally to the writing of the manuscript. AR: followed the patient and revised the manuscript. CJPdS, VH, DSM, AMBR, RC, FT, JFV: performed laboratorial analysis and revised the manuscript.
Competing interests None declared.
Patient consent Obtained.
Ethics approval Centro Hospitalar de Lisboa Ocidental ethics board.
Provenance and peer review Not commissioned; externally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.